# LUPIN LIMITED

# SAFETY DATA SHEET

**Section 1: Identification** 

Section 1, Identification

Material Metformin Hydrochloride Extended-Release Tablets USP

500 mg and 1000 mg

Manufacturer Lupin Limited

**MADE IN INDIA** 

**Distributor** Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

**United States** 

Tel. 001-410-576-2000 Fax. 001-410-576-2221

# Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion Expected to be non-combustible.

Health Metformin hydrochloride extended-release tablets are contraindicated in

patients with:

• Severe renal impairment (eGFR below 30mL/minute/1.73 m<sup>2</sup>).

• Known hypersensitivity to metformin.

• Acute or chronic metabolic acidosis, including diabetic

ketoacidosis, with or without coma.

**Environment**No information is available about the potential of this product to produce

adverse environmental effects.

## **Section 3: Composition/Information on Ingredients**

Section 3, Composition/information on ingredients

Ingredients CAS

Metformin Hydrochloride USP 1115-70-4

## **Section 4: First-Aid Measures**

Section 4. First-aid measures

**Immediately** give large quantities of water to drink. Never give anything by

mouth to a victim who is unconscious or is having convulsions.

Call a physician immediately.

**Inhalation** Remove to fresh air. If breathing stops, provide artificial respiration.

Get medical attention immediately.

SDS : 134/02 Page 1 of 5

Skin Contact Wash off immediately with plenty of water. Continue to rinse for at least

15 minutes. Immediately take off all contaminated clothing.

Get medical attention if irritation develops and persists.

Eye Contact In case of eye contact, remove contact lens and rinse immediately with

plenty of water, also under the eyelids, for at least 15 minutes. Get medical

attention.

#### **NOTES TO HEALTH PROFESSIONALS**

Medical Treatment Treat according to locally accepted protocols. For additional guidance,

refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the

patient's vital signs, blood gases, serum electrolytes, etc.

**OVERDOSAGE** Overdose of metformin HCl has occurred, including ingestion of amounts

greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases. Metformin is dialyzable with a clearance of up to 170 mL/minute under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients

in whom metformin overdosage is suspected.

# **Section 5: Fire-Fighting Measures**

Section 5, Fire-fighting measures

Fire and Explosion Hazards Assume that this product is capable of sustaining combustion.

**Extinguishing Media** Water spray, carbon dioxide, dry chemical powder or appropriate foam.

**Special Firefighting Procedures** For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus

and full protective equipment are recommended for firefighters.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected when the

product is exposed to fire.

#### **Section 6: Accidental Release Measures**

Section 6, Accidental release measures

**Personal Precautions** Wear suitable protective clothing, gloves and eye/face protection.

**Environmental Precautions** Avoid release to the environment.

Clean-up Methods Collect and place it in a suitable, properly labeled container for recovery or

disposal.

# **Section 7: Handling and Storage**

Section 7, Handling and storage

Handling No special control measures required for the normal handling of this

product.

SDS : 134/02 Page 2 of 5

Normal room ventilation is expected to be adequate for routine handling of this product.

Storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F); [see USP Controlled Room Temperature].

# **Section 8: Exposure Controls/Personal Protection**

#### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

## **Section 9: Physical and Chemical Properties**

#### Section 9, Physical and chemical properties

#### **Physical Form**

Metformin hydrochloride extended-release tablets USP, 500 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L41" on one side and "LU" on the other side.

Metformin hydrochloride extended-release tablets USP, 1,000 mg are available as white to off-white, oval shaped, biconvex coated tablet, debossed with "L42" on one side and "LU" on the other side.

They are supplied as follows:

Strength	Package	NDC Code
500 mg	Bottles of 100	68180-338-01
500 mg	Bottles of 500	68180-338-02
500 mg	Bottles of 1000	68180-338-03
1000 mg	Bottles of 90	68180-339-09
1000 mg	Bottles of 100	68180-339-01
1000 mg	Bottles of 500	68180-339-02

# **Section 10: Stability and Reactivity**

#### Section 10, Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport.

## **Section 11: Toxicological Information**

#### Section 11, Toxicological information

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies have been performed in Sprague Dawley rats at doses of 150, 300, and 450 mg/kg/day in males and 150, 450, 900, and 1,200 mg/kg/day in females. These doses are approximately 2, 4, and 8 times in males, and 3, 7, 12, and 16 times in females of the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female rats. A carcinogenicity study was also performed in Tg.AC transgenic mice at doses up to 2,000 mg applied dermally. No evidence of carcinogenicity was observed in male or female mice.

SDS : 134/02 Page 3 of 5

Genotoxicity assessments in the Ames test, gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes) and *in vivo* mouse micronucleus tests were negative. Fertility of male or female rats was not affected by metformin when administered at doses up to 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.

# **Section 12: Ecological Information**

## **Section 12: Ecological Information**

No relevant studies identified.

# **Section 13: Disposal Considerations**

#### **Section 13: Disposal Considerations**

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

# **Section 14: Transport Information**

#### **Section 14: Transport Information**

## IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

#### IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

#### DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

# **Section 15: Regulatory Information**

#### **Section 15: Regulatory Information**

This Section Contains Information relevant to compliance with other Federal and/or state laws.

SDS : 134/02 Page 4 of 5

## **Section 16: Other Information**

## Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 134/02 Page 5 of 5